Neuromodulation Devices Global Market

–Forecast to 2026

Neuromodulation Devices Global Market estimated to be worth $9.9 billion by

2026

IQ4I Research & Consultancy published a new report on “Neuromodulation Devices

Global Market – Forecast To 2026” This report analyzes and studies the overall market,
major Drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific
and Rest of the World.

IQ4I’s Report Contains 108 market data tables and 77 figures spread through 421
pages and an exhaustive TOC on “Neuromodulation Devices Global Market”, [By
Products {Internal Neuromodulation Devices (Spinal Cord Stimulation (SCS), Deep Brain
Stimulation (DBS), Sacral Nerve Stimulation (SNS), Vagus Nerve Stimulation (VNS) and
others), External Neuromodulation Devices (Transcutaneous Electrical Nerve Stimulation
(TENS), Neuromuscular Electrical Stimulation (NMES) and others), by Application {Pain
Management (Chronic Pain, FBSS, and Others), Central Nervous System (Parkinson's
Disease, Essential Tremors, Dystonia, Epilepsy, Depression and others), Gastroenterology
and Urology (Gastroparesis, Urinary Incontinence, Faecal Incontinence) and Others
(Diaphragm pacing, Obstructive sleep Apnea, Diabetes neuropathy, Heart failure, Obesity
and Rheumatoid arthritis)}, by End-Users (Hospitals and ASCs, Clinics and Physiotherapy
Centers, Academics and Research), by Region (North America, Europe, Asia-Pacific and
Rest of the World)].
Neuromodulation is the alteration or modulation of nerve activity by delivering electrical or
magnetic field directly to a target area for the treatment of various conditions such as pain
management, central nervous system disorders, gastroenterology and urology, and other
disorders. Neuromodulation treatment is considered when all other conventional methods fail
to improve the condition of the patient. The Internal neuromodulation devices are designed
to deliver electrical stimulation through an electrode (leads) that are placed inside the body
through a traditional or minimally invasive procedure. Internal neuromodulation devices acts
directly upon nerves to alter or modulate the nerve activity in the target area resulting in
alleviation of pain, restoration of bowel and bladder control, reduction in symptoms of
parkinson’s, epilepsy, essential tremors and others. External neuromodulation devices are
either placed or moved at specific locations over the body to deliver therapy for chronic pain,
diabetic neuropathy, depression and others. Some the common nerve targets used for
stimulations are sacral nerve, peripheral nerve, vagus nerve, phrenic nerve, posterior tibial
nerve, cranial nerve, hypoglossal nerve and others.

According to IQ4I Research analysis, the neuromodulation devices global market is

expected to grow at a high single digit CAGR to reach $9,917.0 million by 2026. Some of the
factors driving the market are increasing incidence of chronic pain, increasing Parkinson’s
and Alzheimer’s diseases, low approval rate of CNS drugs, favorable reimbursement
scenario in major markets, the emergence of neuromodulation as an add-on therapy,

IQ4I Research & Consultancy Pvt. Ltd. Page 1

Neuromodulation Devices Global Market

–Forecast to 2026

technological innovations, rise in the number of clinical studies performed and expansion in
emerging markets. However, there are several obstacles like side effects and risks
associated with the use, availability of alternative treatments, lack of trained professionals
and stringent regulatory guidelines.

The neuromodulation devices market is classified into product, application, end-user, and
geography. Based on the product, the market is segmented as internal and external
neuromodulation devices. The Internal neuromodulation devices segment accounted for the
largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to
2026. Among internal neuromodulation devices, spinal cord stimulator (SCS) segment
accounted for the largest share in 2019 and is expected to growing at a high single digit
CAGR from 2019 to 2026 due to increase in the incidence of chronic pain. Among external
neuromodulation devices, transcutaneous electrical nerve stimulation (TENS) segment
accounted for the largest share in 2019 and is expected to growing at a low single digit
CAGR from 2019 to 2026.

Among various applications, Pain management holds the largest share in 2019 and is
expected to growing at a high single digit CAGR from 2019 to 2026 due to increase in the
prevalence of chronic pain, failed back surgery disorder, migraine, and ischemia. Among
various end-user, Hospitals and Ambulatory surgery centers accounted for the largest share
in 2019 and is expected to growing at a high single digit CAGR from 2019 to 2026 due to
availability of a wide range of treatments and improved patient safety.

The Neuromodulation devices market by geography is segmented into North America,

Europe, Asia-Pacific and Rest of the world regions. North America region dominated the
neuromodulation devices global market with a largest share in 2019 and it is expected to
grow at a high single digit CAGR from 2019 to 2026, mainly due to high technological
advancements, growing awareness about medical care, treatment style, increase in the
aging population, strong product pipeline, new indications, investments and funds, increase
in neurological disease population, sophisticated infrastructure related to healthcare and
high expenditure present among the population of North America are boosting the
neuromodulation devices market. The Asia-Pacific region is the fastest-growing region with a
double digit CAGR from 2019 to 2026, due to rising incidences of neurological disorders,
government initiatives to increasing awareness by education campaigns, large pool of
patients, increasing geriatric population, advancements in surgeries and technologies,

IQ4I Research & Consultancy Pvt. Ltd. Page 2

Neuromodulation Devices Global Market

–Forecast to 2026

increased healthcare facilities, increasing adoption of implantable devices, skilled personnel

and low-cost for the surgery are driving the market.

Neuromodulation devices market has huge opportunity for existing players and new
entrants, the neuromodulation device manufacturers can develop and launch new products
to gain the sparely occupied market. According to IQ4I analysis, in U.S. it is estimated that 1
million people have parkinson’s disease, of that 850K people are eligible for treatment. In
2019, the total implanted Deep brain stimulators (DBS) to treat parkinson’s disease are
estimated to be xx devices, indicating a penetration rate of x.x% with an opportunity of x.x %
in the market.

Some of the companies are coming up with new technological advancements to maintain
their leadership status in the neuromodulation devices market. For instance, Saluda Medical
(Australia) has developed Evoke ECAP controlled closed loop spinal cord stimulation (SCS)
system for patients suffering from chronic pain which received CE mark approval in
September 2019. It is a first closed-loop SCS system that measure’s the spinal cords
response to stimulation and adjusts on every pulse.

Players in this market have adopted product approval strategy to take a better global
position. For instance, in September 2019, Axonics Modulation Technologies, Inc. (U.S.)
received USFDA approval for Axonics r-SNM System, an implantable sacral
neuromodulation device for the treatment of urinary and bowel dysfunction. In August 2019,
CVRx, Inc. (U.S.) a private medical device company received Premarket Approval (PMA)
from USFDA to market BAROSTIM NEO device to treat chronic heart failure and this device
has also received CE Mark approval for sale in Europe.

The neuromodulation devices market is highly consolidated with the top five players
occupying x.x% of the market share and the remaining x.x% of the market is occupied by
other players. The top players in the market are Medtronic Plc (Ireland), Abbott Laboratories
(U.S.), Boston Scientific Corporation (U.S.), LivaNova Plc (U.K.), Nevro Corporation (U.S.),
Inspire Medical Technologies (U.S.), Nuvectra (U.S.), Neuropace Inc. (U.S.), Bioness Inc.
(U.S.), Beijing PINS Medical Co., Ltd. (China), Neuronetic (U.S.) and Laborie Medical
Technologies, Inc. (Canada).

IQ4I Research & Consultancy Pvt. Ltd. Page 3

Neuromodulation Devices Global Market

–Forecast to 2026

Reasons for buying this report:

 Neuromodulation devices global market is projected to reach $9,917.0 million by
2026 at a CAGR of x.x%.
 Identification and analysis of the neuromodulation devices market by identifying
various segments.
 Identification and analysis of neuromodulation market segments by product,
application, end-user and geography.
 Revenue forecast of neuromodulation devices market and strategic analysis of each
sub segment with respect to segmental growth trends.
 Identification of major market trends, Porter's model, factors driving and restraining
neuromodulation devices market.
 Analysis of average selling price (ASP), overall market share, market share analysis
of major products, number of devices in different regions, regulatory approval
analysis of major products, market penetration, reimbursement scenario, funding
scenario, clinical trials and supply chain of neuromodulation devices.
 Identification of key technology developments and innovations driving the market.
 Analysis of the opportunities for stakeholders by identifying the high-growth
segments of the market.
 Revenue forecast of neuromodulation devices market with respect to North America
(U.S., Rest of North America), Europe (Germany, France, U.K. and Rest of Europe),
Asia-pacific (Japan, China, India and Rest of Asia-Pacific) and Rest of the World
(Brazil, Rest of Latin America, Middle East and Others).
 Profiles of major players in neuromodulation devices market and analysis of their
product offerings, financial revenue, business strategies, SWOTs and market shares.

IQ4I Research & Consultancy Pvt. Ltd. Page 4

Neuromodulation Devices Global Market

–Forecast to 2026

FIGURE 1

NEUROMODULATION DEVICES GLOBAL MARKET SEGMENTATION

Neuromodulation Devices Global Market

Product Application End-User Region

Pain GE & Hospitals and North

Internal External CNS Others ASCs America
Management Urology

SCS TENS Chronic Clinics Europe

Parkinson's Gastroparesis Obesity
Pain

DBS Diaphragm Academics Asia-Pacific

NMES Essential Urinary
FBSS Pacing & Research
Tremors Incontinence
TMS, FES, Rest of the
SNS Migraine & Diabetic World
ECT, TNS, Faecal
Ischemia Dystonia Neuropathy
PONS, tDCS Incontinence

VNS Obstructive
Epilepsy Sleep Apnea
GES, RES,
HGNS Heart
Depression Failure

Rheumatoid
OCD, Arthritis
Anxiety

IQ4I Research & Consultancy Pvt. Ltd. Page 5